Evofem Biosciences Inc. (EVFM)
Symbol Info
Listed Symbol EVFM
Name Evofem Biosciences Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-6.80
Price Info
21 Day Moving Average $5.0967
21 Day EMA $5.158890
50 Day Moving Average $5.5138
50 Day EMA $5.227210
200 Day EMA $4.704330
200 Day Moving Average 4.333630
52 Week High $7.24
52 Week Low $2.03
52 Week Change $129.032300
Alpha 0.032499
Beta 0.6431
Standard Deviation 0.404819
R2 0.003152
Periods 57
Share Information
10 Day Average Volume 32,445
20 Day Average Volume 34,336
30 Day Average Volume 37,617
50 Day Average Volume 106,229
Outstanding Shares 46,601,058
Float Shares 45,143,238
Percent Float 96.87%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 50
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 2,204,677
Institute Holdings Percent 74.700000
Institute Sold Previous 3 Months 338,336
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months 4,292
Insider Holdings Percent 3.10%
Insider Sold Previous 3 Months 655
Insiders Shares Owned 1,457,820
Price Change
7 Day Price Change $-0.0800004
7 Day Percent Change -1.58%
21 Day Price Change $-0.02
21 Day Percent Change -0.40%
30 Day Price Change $0.2399998
30 Day Percent Change 5.07%
Month To Date Price Change $0.1100
Month To Date Percent 2.26%
90 Day Price Change $-0.05
90 Day Percent Change -1.00%
Quarter To Date $-1.67
Quarter To Date Percent -25.15%
180 Day Price Change $1.370000
180 Day Percent Change 38.06%
200 Day Price Change $1.490000
200 Day Percent Change 42.82%
Year To Date $0.780000
Year To Date Percent 18.62%
Profile
Description Evofem Biosciences Inc provides woman-controlled protection from sexually transmitted infections. It addresses women's unmet medical needs through the discovery, development and commercialization of healthcare products. Evofem's products that are in development phase include Amphora primarily for the prevention of pregnancy and prevention of urogenital chlamydia and gonorrhea.
Details
Issue Type CS
Market Cap $231,607,258
Sec Type EQS
Auditor Deloitte & Touche LLP
Total Shares Outstanding 46,601,058
CEO Saundra Pelletier
Employees 30
Last Audit UE
Classification
CIK 0001618835
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 12400 High Bluff Drive
Suite 600
San Diego, CA 92130
Website http://www.evofem.com
Facisimile +1 844 828-2010
Telephone +1 858 550-1900
Email araskopf@evofem.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $190,362,459
Price To Sales -
Price To Free Cash -5.2
PE High Last 5 Years -
Price To Book 6.7
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 6.7
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 2.8
Leverage Ratio -2.9
Quick Ratio 2.7
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -215.75
Return On Equity -423.53
Return On Capital -412.8
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
EVFM
Evofem Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.